EGFR and neoplasm: In lung ADC, the first example of successful targeted therapy is the pharmacological inhibition of the epidermal growth factor receptor (EGFR) with increasing survival of patients with actionable tumor EGFR mutations receiving EGFR tyrosine kinase inhibitors (TKI) [7].